

Index

- ACC. *See* Acyl-CoA carboxylase
- ACCORD. *See* Action to Control Cardiovascular Risk in Diabetes
- Action to Control Cardiovascular Risk in Diabetes (ACCORD), 47–48
- Acyl-CoA carboxylase (ACC), 98
- AD. *See* Alzheimer's disease
- ADME, 18
- ADNI. *See* Alzheimer's Disease Neuroimaging Initiative
- ADOPT study, 44
- Adsorption, distribution, metabolism and elimination (ADME), 18
- Alendronate, 142–143
- $\alpha_v\beta_3$ integrin antagonists, 127–130
 animal models, 128–129
 echistatin, 127–128
 expression, 127–128
 human data, 130
 POC mechanism, 130
- Alzheimer's disease (AD), 235–236
- Alzheimer's Disease Neuroimaging Initiative (ADNI), 235–236, 299–300
- American Diabetes Association, 35, 48
- Aminorex, 90
- AMP-activated protein kinase (AMPK), 96
- AMPK. *See* AMP-activated protein kinase
- Anacetrapib, 76, 82
- Angiography, atherosclerotic biomarkers, 78–79
- Antibiotics, POM, 12–13
 MIC, 12–13
- Antidepressants. *See* Selective serotonin reuptake inhibitors
- Antidyslipidemics, 69–77
 ASO, 75
 CETP inhibitors, 75–77
 anacetrapib, 76, 82
 dalcetrapib, 76, 82
 PPAR- α agonists, 76–77
 reconstituted and recombinant HDL/ApoA-I mimetic peptides, 77
 torcetrapib, 76, 80–82
- cholesterol absorption inhibitors, 72
- EPA/DHA, 71–72
- fibrates, 71
- fish oil, 71–72
- Lp-PLA2 inhibitors, 73–74
- MTP inhibitors, 74
- niacin therapy, 70–71
 extended release, 70
 flushing effects, 70–71
 laropiprant, 70–71
- phytosterols, 73
- sPLA2 inhibitors, 74
- statins, 72
- thyroid receptor- β agonists, 73
- Antiresorptives, bone disorder therapy, 121–130
 $\alpha_v\beta_3$ integrin antagonists, 127–130
 animal models, 128–129
 echistatin, 127–128
 expression, 127–128
 human data, 130
 POC mechanism, 130

- Antiresorptives (*cont.*)
 cathepsin K inhibitors, 122–127
 animal models, 122–124
 balicatib, 125
 expression, 122
 human data, 124–127
 odanacatib, 122, 125
 phases, 121
- Antisense oligonucleotides (ASO),
 75
- Antivirals, 13–14
- Apoptosis, imaging for, 244–245
- ASO. *See* Antisense oligonucleotides
- Asthma, therapies for, under IML,
 283
- Atherosclerosis, translational medicine
 for, 62–82
 antidyslipidemics, 69–77
 ASO, 75
 CETP inhibitors, 75–77
 cholesterol absorption
 inhibitors, 72
 EPA/DHA, 71–72
 fibrates, 71
 fish oil, 71–72
 Lp-PLA2 inhibitors, 73–74
 MTP inhibitors, 74
 niacin therapy, 70–71
 phytosterols, 73
 sPLA2 inhibitors, 74
 statins, 72
 thyroid receptor- β agonists, 73
- biomarkers, 77–80
 angiography for, 78–79
 carotid intima-media thickness,
 79
 with CAT scan, 80
 clinical outcome prediction,
 78
 with FMD, 79
 imaging, 245–247
 with IVUS, 79–80
 with PET scan, 80
 vascular function and, 78–80
- CETP inhibitors, case studies, 76,
 80–82
 Phase 2 trials, 81
 Phase 3 study, 81
- developmental theories, 62–65
- drug development, 67
 antidyslipidemics, 69–77
 lipoprotein metabolism, 67–69
- HDL cholesterol, 65–67
- hypertension and, 65
 imaging biomarkers, for drug
 development, 245–247
 in clinical trials, 246
 modality types, 245–246
 practicality, 247
 for presentation of symptoms,
 245
- incidence rates, 62
- inflammation, 65
- LDL cholesterol, 62
 lipid infiltration hypothesis, 63,
 65
- lipid infiltration hypothesis, 62–63
 clinical trial support, 65
 hypercholesterolemia, 63
 LDL cholesterol levels, 63, 65
 plasma cholesterol levels, 63
- lipoprotein metabolism, 67–69
 cholesterol levels, 67–68
 triglycerides, 67
- mortality rates, 62
- obesity and, 62, 89
- response to inflammation
 hypothesis, 64
- response to injury hypothesis,
 63–64
- response to retention hypothesis,
 64–65
- risk factors, 65–66
- Atorvastatin, 16, 30–31
- Balicatib, 125
 adverse effects, 125–126
- Bayh-Dole Act, 328
- β agonists, 102
- β cells, type 2 diabetes, 35
- DMAD agents, 43–46
 ADOPT study, 44
 cell mass improvement, 46
 DI, 44–45
 glucolipototoxicity, 46
 HOMA, 44
 improvement measures, 45–46
 insulin secretion improvement,
 45
 monotherapy failure delay, 45
 post-washout function, 45
 UKPDS, 44
- under IML, 282
- pathophysiology, 43
- preservation, 43–46
- BIIF. *See* Business impact if false (BIIF),
 for biomarker research
- Bile acid sequestrants, 70

- Binding potential (BP), 224–225
- Biomarkers, in translational medicine,
4, 5–7, 195–203. *See also*
Endpoint biomarkers;
Imaging biomarkers, in drug
development
- atherosclerosis, 77–80
angiography for, 78–79
carotid intima-media thickness,
79
with CAT scan, 80
clinical outcome prediction,
78
with FMD, 79
with IVUS, 79–80
with PET scan, 80
vascular function and, 78–80
- behavioral, 10–11
- business value of, 200–202
BIIF, 203–204
purpose of, 203–205
tradeoff optimization for,
200–201
for validation, 202
- definition, 5, 195
- diagnostic, 5
- in drug development, 7, 195–203,
215–221
clinical outcome linkage, 221
clinical study optimization,
207
after exploratory development
decision, 216–218
Phase 1 studies, 207–209, 219
Phase 2 studies, 218–220, 221
purpose, 216
risk assessment, 216
during 21st century, 332–333
- Expl-IND, 24–26
behavioral v. biochemical,
10–11
- imaging, 222–249
cardiovascular disease, 245–247,
248
DCE-MRI, 239–241
fMRI, 228–235
H-MRS, 242–243
in oncology, 236–245
with PET, 224–228
purpose of, 222–224
in study population, 235–236
- lifecycle stages, 198–199
hypothesis/objective
definitions, 198–199
- MAC fulfillment, 199
pathfinding, 198
species POC, 199
- MAC, 197, 199, 209–215
clinical outcome linkage to,
211–212
content of, 210
fallback positions for, 211
performance targets in,
210–211
- mechanism, 6, 184–185, 196
- neuroscience applications,
174–175
stop-signal tasks, 174–175
- obesity drug development,
103–106
clinical studies, 105–106
for disease process, 105–106
drug pharmacology, 104–105
for efficacy outcomes, 105–106
target mechanisms, 103–104
- oncology, 180–187
outcome, 180–183
patient selection, 185–187
pharmacodynamic, 180–183
- osteoporosis, 116–121
BMD, 116
bone formation, 119, 120
bone turnover, 116–117, 118
- outcome, 6, 196
linkage to, 6
in oncology, 183–185
- principles, 195–197
for validation, 196–197
for value, 196
- purpose of, 202–205
business value principles,
203–205
definition of, 202
evidence gathering relevance,
202
performance relevance, 203
- qualification, 7. *See also* Validation
- surrogate endpoint, 5–6
- target, 6, 196
- technical validation, 7, 197
attribute selection, 205–207
- translation, 7
- type 2 diabetes, 38
glycemic, 38
- types, 196
linkage to, 6
mechanism, 6
outcome, 6

- Biomarkers (*cont.*)
 target, 6
 uses in drug development, 7
 POC, 7
 POM, 7
 validation, 7, 195–203
 business value of, 202
 clinical, 7
 definition, 195
 MAC, 197, 199, 209–215
 principles for, 196–197
 technical, 7
 terminology, 197–198
 translation, 197
 validity within, 197
- Biomarkers Consortium, 295–300
 ADNI, 235–236, 299–300
 FNIH, 295–296, 297
 medical areas of interest,
 296–297
 projects list, 297
- Biomedical Informatics Research
 Network (BIRN), 235
- Biotechnology revolution, 328–329
- BIRN. *See* Biomedical Informatics
 Research Network
- Bisphosphonate therapy, for bone
 disorders, 119
- “Blockbuster” drugs, 28
- Blood oxygen-level dependent
 (BOLD) responses,
 230–233
- BMD. *See* Bone mineral density
- BOLD responses. *See* Blood
 oxygen-level dependent
 responses
- Bone disorders. *See* Osteoarthritis;
 Osteoporosis; Sclerosteosis
- Bone formation, 117–118
 biomarkers, 119, 120
 sclerostin, 155
- Bone mineral density (BMD), 116,
 118–119
 bisphosphonate therapy, 119
 fracture risk, 119
- Bone turnover, 116–118
 biomarkers, 116–117, 118
 calcilytics, in animal models,
 140–141
 osteoblasts, 117–118
 osteoclasts, 117
 SARMs, 135–136
- BP. *See* Binding potential
- Bupropion, 101
- Business impact if false (BIIF), for
 biomarker research,
 203–204
- Byetta. *See* Exenatide
- Calcilytics, 136–144
 animal models, 140–142
 bone turnover, 140–141
 CaR, 137–140
 GPCRs, 137–138
 physiological relevance, 138
 in treatment therapies, 137
 early compounds, 139–140
 expression, 136–140
 human data, 142–144
 POC mechanisms, 142,
 143–144
- Calcium receptor agonists (CaR),
 137–140
 GPCRs, 137–138
 physiological relevance, 138
 in treatment therapies, 137
- CAMD. *See* Coalition against Major
 Disease
- Cannabinoid (CB) receptors, 95
- CaR. *See* Calcium receptor agonists
- Cardiovascular disease. *See also*
 Atherosclerosis, translational
 medicine for
 imaging biomarkers, in drug
 development, 245–247, 248
 in clinical trials, for
 atherosclerosis, 246
 modality types, 245–246
 practicality, 247
 for presentation of symptoms,
 245
 type 2 diabetes, 43
 dyslipidemia, 43
 FMD data, 47
 safety risks, with translational
 medicine, 46–47
- Carnitine palmitoyl transferase (CPT1),
 95
- Carotid intima-media thickness,
 79
- CAT. *See* Computer-aided tomography
- Cathepsin K inhibitors, 122–127
 animal models, 122–124
 odanacatib, 124
 balicatib, 125
 adverse effects, 125–126
 expression, 122
 human data, 124–127

- odanacatib, 122, 125
 animal models, 124
- CB receptors. *See* Cannabinoid receptors
- CCK. *See* Cholecystokinin
- CETP inhibitors, 75–77
 anacetrapib, 76, 82
 dalcetrapib, 76, 82
 PPAR- α agonists, 76–77
 reconstituted and recombinant HDL/ApoA-I mimetic peptides, 77
 torcetrapib, 76, 80–82
 Phase 2 trials, 81
 Phase 3 study, 81
- Cholecystokinin (CCK), 96
- Cholesterol absorption inhibitors, 72
 ezetimibe, 72–73
 simvastatin, 72
- Chronic obstructive pulmonary disease (COPD), therapies for, under IMI, 283
- Cinacalcet, 137, 138
- Circulating tumor cells (CTCs), 185
- Clinical Diabetes Research: Methods and Techniques* (Roden), 41
- Clofibrate, 70
- Clomipramine, 227
- Coalition against Major Disease (CAMD), 290
- Commercial profile, 27–32
 “blockbuster” drugs, 28
 decision making and, 29–31
 personalized medicine options, 31–32
 requirements, 27–28
- Computer-aided tomography (CAT), for atherosclerotic biomarkers, 80
- COPD. *See* Chronic obstructive pulmonary disease (COPD), therapies for, under IMI
- C-Path. *See* Critical Path Institute
- CPT1. *See* Carnitine palmitoyl transferase
- Critical Path Institute (C-Path), 289–293
 CAMD, 290
 EMA, 292
 as financially independent, 289–290
 PRO, 290
 PSTC, 290–293
- CTCs. *See* Circulating tumor cells
- Dalcetrapib, 76, 82
- Darapladib, 74
- Darwin, Charles, 341
- DCE-MRI. *See* Dynamic contrast enhanced MRI
- Depression
 drug development, 170–171
 NMDA, 171
 under IMI, 282
 obesity treatment therapies, 100–101
- Desoxyephedrine, 89
- Dexfenfluramine, 90
- DGAT. *See* Diacylglycerol acyltransferase
- DI. *See* Disposition index
- Diacylglycerol acyltransferase (DGAT), 98–99
- Diagnostic biomarker, 5
- Dickkopf-1 (DKK-1) inhibitors, 144–149
 animal models, 146–149
 expression, 144–146
 human data, 149
 Wnt signaling, 144–145
- Dipeptidyl peptidase-IV inhibitors (DPP-4i), 38
 development, 49–50
 phase trials, 49–50
 GLP1, 49
- Disease-modifying antidiabetic (DMAD) agent, 43–46
 ADOPT study, 44
 cell mass improvement, 46
 DI, 44–45
 glucolipototoxicity, 46
 HOMA, 44
 improvement measures, 45–46
 insulin secretion improvement, 45
 monotherapy failure delay, 45
 postwashout function, 45
 UKPDS, 44
- Disposition index (DI), 44, 45
- DKK-1 inhibitors. *See* Dickkopf-1 inhibitors
- DMAD agents. *See* Disease-modifying antidiabetic agent
- Docosahexaenoic acid. *See* Eicosapentaenoic acid/docosahexaenoic acid
- DPP-4i. *See* Dipeptidyl peptidase-IV inhibitors

- Drug development
- atherosclerosis, 67
 - lipoprotein metabolism, 67–69
 - biomarkers in, 7, 195–203, 215–221
 - clinical outcome linkage, 221
 - clinical study optimization, 207
 - after exploratory development
 - decision, 216–218
 - imaging, 222–249
 - obesity therapies, 104–105
 - Phase 1 studies, 207–209, 219
 - Phase 2 studies, 218–220, 221
 - purpose, 216
 - risk assessment, 216
 - during 21st century, 332–333
 - under IMI, in EU, 278–279
 - modeling and simulation in,
 - 303–325
 - current paradigms, 303–304, 305–306
 - franchise disease–drug models, 307–311
 - improvement strategies, 315–324
 - MBDD, 303–304
 - pharmacometric process, 304–305
 - results delivery challenges, 311–314
 - neuroscience applications, 168–176
 - animal models, 170
 - challenges, 168–169
 - depression, 170–171
 - duloxetine, 168–169
 - 5-HT_{2A} receptors, 172–173
 - future approaches, 175–176
 - mechanism failures in, 169–173
 - mGLU2/3 receptor agonists, 170, 171
 - MTD definitions, 168
 - SERT radiotracers, 168–169
 - obesity biomarkers, 104–105
 - enzymes, 105
 - peptides, 104
 - oncology, in translational medicine, 180–191
 - biomarkers, 180–187
 - outcome biomarkers, 183–185
 - patient selection biomarkers, 185–187
 - pharmacodynamic biomarkers, 180–183
 - Phase 1 study design, 189
 - Phase 2 study design, 190
 - preclinical work, 188–189
 - for osteoporosis, 116
 - biomarkers, 116
 - targeting mechanisms, 116
 - PK-PD models, for biomarkers, 207–209
 - in 21st century, 328–343
 - animal/human studies, 333
 - biomarkers, 332–333
 - biotechnology revolution, 328–329
 - business acquisitions and, 339–343
 - democratization of discovery, 331, 336–337
 - diversification of knowledge pathways, 337–339
 - in experimental medicine, 331–332, 334–336
 - failure costs, 332–333
 - legislation, 328, 329
 - partnerships between companies, 339–343
 - for personalized medicine, 342
 - Phase 2 trials, 330–331
 - primary care disease, 342
 - R&D investment, 329–330
 - Drug discovery strategies. *See also* Proof of mechanism
 - NCEs, 3
 - translational medicine, 3
 - Drug targets, 3
 - Duloxetine, 168–169
 - Dynamic contrast enhanced MRI (DCE-MRI), 239–241
 - Dyslipidemia, 43
 - Echistatin, 127–128
 - Efficacy endpoint biomarkers, 19–20
 - population influences, 19–20
 - Eicosapentaenoic
 - acid/docosahexaenoic acid (EPA/DHA), 71–72
 - 11 β -hydroxysteroid dehydrogenase type 1 (11 β HSD1), 50–54, 99–100
 - EMA. *See* European Medicines Agency
 - Endpoint biomarkers
 - efficacy, in POC study design, 19–20
 - POM study designs, 15
 - surrogate, 5–6
 - Energy balance, in obesity treatment therapy, 89

- drug targets, 90–91
- leptin, 91
- molecular pathways, 90–91
- NEAT, 90
- pathophysiology, 90–91
- translational approaches, 102–103
- EPA/DHA. *See* Eicosapentaenoic acid/docosahexaenoic acid
- European Medicines Agency (EMA), 292
- Exenatide, 96, 101–102
- Experimental medicine, 4
 - drug development for, 331–332, 334–336
- Experimental medicine organizations
 - POC, 4
 - POM, 4
 - translational v., 4–5
- Expl-IND. *See* Exploratory Investigational New Drug Application
- Exploratory Investigational New Drug Application (Expl-IND), 24–26
 - dosing guidelines, 25
 - efficacy of biomarker signals, 25–26
 - pharmacologically active dose, 25–26
 - POV, 26
- Ezetimibe, 72–73
- FDA. *See* Food and Drug Administration
- Fenfluramine, 101
- Fenofibrate, 71
- Fibrate therapy, 71
 - Trilipix, 71
- Fish oil, 71–72
- 5-HT_{2A} receptors, 172–173
- Flow-mediated dilation (FMD), 47
 - for atherosclerotic biomarkers, 79
- FMD. *See* Flow-mediated dilation
- FNIH. *See* Foundation for National Institutes of Health
- Food and Drug Administration (FDA), weight loss drugs, 41–43
- Foundation for National Institutes of Health (FNIH), 295–296, 297
- franchise disease–drug models, 307–311
 - data definitions, 310
 - development, 309
 - future implications, 310–311
 - improvement strategies, 319–322
 - for translational medicine, 307–308
 - for type 2 diabetes therapies, 308–309
- Functioning magnetic resonance imaging (fMRI), for biomarkers, in drug development, 228–235
- BOLD responses, 230–233
- NMDA, 230–232
- patient population studies, 233–234
- phMRI, 229
- remifentanyl, 232
- resting state functional connectivity, 229
- standardization of, 234–235
- task-evoked, 229
- validation of, 235
- Ghrelin *O*-acyl transferase (GOAT), 97–98
- GHSR. *See* Growth hormone secretagogue receptor
- Gleevec. *See* Imatinib
- GLP1. *See* Glucagon-like peptide 1
- Glucagon-like peptide 1 (GLP1), 49
 - obesity treatment, 96
- Glucose lowering, type 2 diabetes, 37–41
 - biomarkers, 38
 - glycemic, 38
 - glucose-dependence, 38
 - glycemic biomarkers, 38
 - HbA1c units, 37–38
 - IVGTT, 41
 - MMTTs, 41
 - OGTTs, 39, 41
 - Phase 1 trials, 38
 - biomarkers, 38
 - DPP-4i, 38
 - dynamic tests, 40, 42
 - OGTTs, 39
 - population selection, 39
 - static measures, 40
 - Phase 2 studies, 37–38
 - HbA1c units, 37–38
 - system perturbation introduction, 40–41
 - systemic mechanisms, 38–39
 - insulin secretion, 38–39
- Glycemic biomarkers, 38
- GOAT. *See* Ghrelin *O*-acyl transferase
- GPCRs. *See* G-protein coupled receptors

- G-protein coupled receptors (GPCRs),
92
CaR, 137–138
- Growth hormone secretagogue
receptor (GHSR), 97
- Haloperidol, 225–226
- Hatch–Waxman Act, 329
- HbA1c units, 56
obesity, type 2 diabetes
development, 41, 43,
54–56
- HDL cholesterol, 65–67
- History
experimental medicine, 4
translational medicine, 4
- H-MRS. *See* Proton magnetic
resonance spectroscopy
- HOMA. *See* Homeostasis Model
Assessment
- Homeostasis Model Assessment
(HOMA), 44
- Hormones. *See* Thyroid receptor- β
agonists
- Human indications screening,
23–27
costs, 26–27
efficacy signals, 23–24
Expl-IND approach, 24–26
dosing guidelines, 25
efficacy of biomarker signals,
25–26
POV, 26
Phase 3 trials, 22
POM, 23
portfolio economics, 26–27
POV, 26–27
Expl-IND approach, 26
- Hypercholesterolemia, 63
- Hypertension
atherosclerosis and, 65
from obesity, 89
- Hypoglycemia, 47–49
ACCORD study, 47–48
drug development, 48
stepped clamps, 48–49
VADT, 47–48
- Imaging biomarkers, in drug
development, 222–249
cardiovascular disease, 245–247,
248
in clinical trials, for
atherosclerosis, 246
modality types, 245–246
practicality, 247
for presentation of symptoms,
245
- DCE-MRI, 239–241
fMRI, 228–235
BOLD responses, 230–233
NMDA, 230–232
patient population studies,
233–234
pHMRI, 229
remifentanyl, 232
resting state functional
connectivity, 229
standardization of, 234–235
task-evoked, 229
validation of, 235
- H-MRS, 242–243
in oncology, 236–245
anatomical applications,
236–237
for apoptosis, 244–245
for cellular proliferation,
242–244
DCE-MRI, 239–241
functional, 237–239
H-MRS, 242–243
PERCIST guidelines, 238–239
RECIST guidelines, 237, 238–239
for tumor receptors, 244
for tumor vasculature, 239–241
- PET, 224–228
for antipsychotics, 224–226
BP, 224–225
case study, 227–228
plasma kinetics, 226
receptor occupancy, 224–225
for SERT, 226–227
for SSRIs, 226–227
purpose, 222–224
in study population, 235–236
for AD, 235–236
- Imatinib, 28
- IMI. *See* Innovative Medicines
Initiatives
- Innovative Medicines Initiatives (IMI),
265–287
asthma therapies, 283
call procedures, 285
chronic pain therapies, 282
COPD therapies, 283
depression therapies, 282
development history, 267–272,
273

- NSMF, 266, 267–268, 271
workshops, 272
- drug development applications
under, 278–279
- education and training programs,
283–285
- efficacy markers, predictive,
274–276, 282–283
- funding sources, in EU, 265–266
- future perspectives, 285–287
- knowledge management, 283
- neurodegenerative disorders,
282–283
- off-target toxicity guidelines,
277–278
- organizational structure, 272–274
- purpose, 265
- safety markers, predictive, 276–277,
281
- schizophrenia therapies, 282
- stakeholders in, 266–267
- support call proposals, 270,
280–285, 286
- type 2 diabetes therapies, 282
 β cell dysfunction, 282
- Insulin secretion, 38–39. *See also*
Glucose lowering, type 2
diabetes
- Intravascular ultrasound (IVUS), 79–80
- Intravenous glucose tolerance test
(IVGTT), 41
- IVGTT. *See* Intravenous glucose
tolerance test
- IVUS. *See* Intravascular ultrasound
- Laropiprant, 70–71
- LCP-AtorFen, 71
- LDL cholesterol
level reductions, 62
lipid infiltration hypothesis, 63
- Leptin, 91
satiety-thermogenesis regulation,
92
- Lipid infiltration hypothesis, 62–63
clinical trial support, 65
hypercholesterolemia, 63
LDL cholesterol levels, 63, 65
plasma cholesterol levels, 63
- Lipitor. *See* Atorvastatin
- Lipoprotein metabolism, 67–69
cholesterol
homeostasis, 68
movement, 67–68
reverse transport, 67–68
triglycerides, 67
- Lipoprotein-associated-phospholipase
A2 (Lp-PLA2) inhibitors,
73–74
- Liraglutide, 96
- Lomitapide, 74
- Look Ahead Trial study, 41
- Lp-PLA2 inhibitors. *See* Lipoprotein-
associated-phospholipase A2
inhibitors
- MAC. *See* Minimally acceptable criteria
(MAC), for biomarkers
- Magnetic resonance spectroscopy. *See*
Proton magnetic resonance
spectroscopy
- Maximal tolerable dose (MTD), 168
pharmacodynamic biomarkers, 181
- MBDD. *See* Model-based drug
development
- MCH. *See* Melanin concentrating
hormone
- Mechanism biomarker, 6, 184–185,
196. *See also* Outcome
biomarkers
- Melanin concentrating hormone
(MCH), 94–95
- Menopause, SARMs therapy, 135
- Metabotropic glutamate_{2/3} (mGLU2/3)
receptor agonists, 170, 171
- mGLU2/3 receptor agonists. *See*
metabotropic glutamate_{2/3}
receptor agonists
- MIC. *See* Minimal inhibitory
concentration
- Microsomal triglyceride transfer
protein (MTP) inhibitors, 74
- Minimal inhibitory concentration
(MIC), 12–13
- Minimally acceptable criteria (MAC),
for biomarkers, 197, 199,
209–215
clinical outcome linkage to,
211–212
content of, 210
fallback positions for, 211
performance targets in, 210–211
- Mipomersen, 75
- Mixed-meal tolerance test (MMTT), 41
- MMTT. *See* Mixed-meal tolerance test
- Model-based drug development
(MBDD), 303–304
in pharmacometric process,
306–307

- Modeling and simulation, in drug development, 303–325
 current paradigms, 303–304, 305–306
 franchise disease–drug models, 307–311
 data definitions, 310
 development, 309
 future implications, 310–311
 improvement strategies, 319–322
 for translational medicine, 307–308
 for type 2 diabetes therapies, 308–309
 improvement strategies, 315–324
 design reviews, 315–316
 franchise disease–drug models, 319–322
 integrated project teams, 315
 for pharmacometric infrastructure, 318–319
 process-oriented approaches in, 316–317
 systemization of requirements, 322–324
 training programs, 317–318
- MBDD, 303–304
 in pharmacometric process, 306–307
- pharmacometric process, 304–305
 MBDD in, 306–307
- results delivery challenges, 311–314
 for informatics needs, 312–313
 for process needs, 313–314
 for systematic needs, 311–312
- MTD. *See* Maximal tolerable dose
- MTP. *See* Microsomal triglyceride transfer protein inhibitors
- Naltrexone, 101
- NCEs. *See* New chemical entities
- NEAT. *See* Nonexercise activity thermogenesis
- Neurodegenerative disorders, therapies for, under IMI, 282–283
- Neuroscience, in translational medicine
 cognitive biomarkers, 174–175
 stop-signal tasks, 174–175
 drug development for, 168–176
 animal models, 170
 challenges, 168–169
 for depression, 170–171
 duloxetine, 168–169
 5-HT_{2A} receptors, 172–173
 future approaches, 175–176
 mechanism failures in, 169–173
 mGLU2/3 receptor agonists, 170, 171
 MTD definitions, 168
 SERT radiotracers, 168–169, 175
 imaging studies, 176
 semagacestat, 175–176
 SERT radiotracers, 168–169, 175
 short-term study efficacy, 173–174
- New chemical entities (NCEs), 3
- New Safe Medicines Faster (NSFM) project, 266, 267–268, 269, 271
- Niacin therapy, 70–71
 extended release, 70
 flushing effects, 70–71
 laropiprant, 70–71
- NMDA. *See* N-methyl-D-aspartate
- N-methyl-D-aspartate (NMDA), 171
 fMRI biomarkers, in drug development, 230–232
- Nonexercise activity thermogenesis (NEAT), 90
- NSFM Project. *See* New Safe Medicines Faster project
- Obesity, 89–108. *See also* Leptin
 atherosclerosis and, 62, 89
 biomarkers, 103–106
 clinical studies, 105–106
 for disease process, 105–106
 drug pharmacology, 104–105
 for efficacy outcomes, 105–106
 target mechanisms, 103–104
 drug targets, 93–94
 ACC, 98
 β agonists, 102
 biomarkers, 103–106
 clinical paradigms, 100–102
 DGAT, 98–99
 11β-HSDI, 99–100
 energy balance, 89, 90–91
 engagement mechanisms, 103–104
 peptide hormone regulation, 96–98
 peripheral pathways, 98–103

- satiety-thermogenesis
 regulation, 92–96
 SCD1, 99
 subject selection, 106–107
 UCP activation, 99
- energy balance, 89
 drug targets, 90–91
 leptin, 91
 molecular pathways, 90–91
 NEAT, 90
 pathophysiology, 90–91
 translational approaches,
 102–103
- hypertension from, 89
- orlistat, 42, 100
- osteoarthritis, 89
- peptide hormone regulation, 96–98
 CCK, 96
 GHSR, 97
 GLP1, 96
 GOAT, 97–98
 OXM, 96–97
- prevalence, 89
- rimonabant, 42, 100
- satiety-thermogenesis regulation,
 92–96
 AMPK activation, 96
 CB regulation, 95
 GPCRs, 92
 leptin levels, 92
 MCH regulation, 94–95
 neuropeptide expression, 92–94
 nutrient sensation, 95–96
 POMC activation, 92
 serotonergic pathway
 regulation, 95
- sibutramine, 42, 100
- treatment therapies
 adverse effects, 100–101
 combination, 100–101, 107
 energy balance, 89
 lifestyle intervention, 89
 pharmacological, 89–90
 subject selection, 106–107
- type 2 diabetes, 41–43, 89
 HbA1c mean levels, 41, 43,
 54–56
 Look Ahead Trial study, 41
 weight loss drugs, development
 of, 41–43
- Odanacetib (ODN), 122, 125
 animal models, 124
- ODN. *See* Odanacetib
- OGTTs. *See* Oral glucose tolerance tests
- Olanzapine, 226
- Oncology, translational medicine in
 drug development, 180–191
 biomarkers, 180–187
 imaging, 236–245
 outcome, 183–185
 patient selection, 185–187
 pharmacodynamic, 180–183
 imaging, of biomarkers, 236–245
 anatomical applications,
 236–237
 for apoptosis, 244–245
 for cellular proliferation,
 242–244
 DCE-MRI, 239–241
 functional, 237–239
 H-MRS, 242–243
 PERCIST guidelines, 238–239
 RECIST guidelines, 237, 238–239
 for tumor receptors, 244
 for tumor vasculature, 239–241
 outcome biomarkers, 183–185
 CTCs, 185
 RECIST as clinical endpoint,
 184–185
 patient selection biomarkers,
 185–187
 hypothesis independent
 approaches, 186–187
 pharmacodynamic biomarkers,
 180–183
 function, 180
 MTD, 181
 traditional Phase 1 dose
 selection, 181–183
 Phase 1 study design, 189
 Phase 2 study design, 190
 preclinical work, 188–189
- Oral glucose tolerance tests (OGTTs),
 39
- Orlistat, 42, 100
- Osteoanabolics, bone disorder therapy,
 130–155
 bone biology, future research on,
 156
 calcilytics, 136–144
 animal models, 140–142
 CaR, 137–140
 early compounds, 139–140
 expression, 136–140
 human data, 142–144
 DKK-1 inhibitors, 144–149
 animal models, 146–149
 expression, 144–146

- Osteoanabolics (*cont.*)
 human data, 149
 Wnt signaling, 144–145
- SARMs, 131–136
 animal models, 132–134
 expression, 131–132
 human data, 134–136
- sclerostin inhibitors, 149–155
 animal models, 151–154
 bone formation, 155
 expression, 149–151
 human data, 154–155
 sclerosteosis, 150
 Van Buchem disease, 150
- Osteoarthritis, from obesity, 89
- Osteoblasts, 117–118
- Osteoclasts, 117. *See also* $\alpha_v\beta_3$ integrin
 antagonists; Antiresorptives,
 bone disorder therapy;
 Cathepsin K inhibitors
- Osteoporosis, 115–158. *See also*
 Antiresorptives, bone
 disorder therapy;
 Osteoanabolics, bone
 disorder therapy
- $\alpha_v\beta_3$ integrin antagonists, 127–130
 animal models, 128–129
 echistatin, 127–128
 expression, 127–128
 human data, 130
 POC mechanism, 130
- antiresorptive therapy, 121–130
 $\alpha_v\beta_3$ integrin antagonists,
 127–130
 cathepsin K inhibitors, 122–127
- biomarkers, 116–121
 BMD, 116, 118–119
 bone formation, 119, 120
 bone turnover, 116–117, 118
 drug therapy response, 118
 osteoblasts, 117–118
 osteoclasts, 117
 preclinical models, 119–121
- BMD, 116, 118–119
 bisphosphonate therapy, 119
 fracture risk, 119
- bone formation, 117–118
 biomarkers, 119, 120
 sclerostin, 155
- bone turnover, 116–117, 118
 osteoblasts, 117–118
 osteoclasts, 117
- calcilytics, 136–144
 animal models, 140–142
 CaR, 137–140
 early compounds, 139–140
 expression, 136–140
 human data, 142–144
- cathepsin K inhibitors, 122–127
 animal models, 122–124
 balicatib, 125
 expression, 122
 human data, 124–127
 odanacatib, 122, 125
- DKK-1 inhibitors, 144–149
 animal models, 146–149
 expression, 144–146
 human data, 149
 Wnt signaling, 144–145
- drug development challenges, 116
 targeting mechanisms, 116
- osteoanabolics, 130–155
 calcilytics, 136–144
 DKK-1 inhibitors, 144–149
 sclerostin inhibitors, 149–155
- presentation, 115
 prevalence, 115
- SARMs, 131–136
 animal models, 132–134
 expression, 131–132
 human data, 134–136
- sclerostin inhibitors, 149–155
 animal models, 151–154
 bone formation, 155
 expression, 149–151
 human data, 154–155
 sclerosteosis, 150
 Van Buchem disease, 150
- treatment therapies, 115
 alendronate, 118
 antiresorptives, 121–130
 osteoanabolics, 130–155
- Outcome biomarkers, 6, 196
 linkage to, 6
 high, 6
 low, 6
 medium, 6
 in oncology, 183–185
 CTCs, 185
 RECIST as clinical endpoint,
 184–185
- OXM. *See* Oxyntomodulin
- Oxyntomodulin (OXM), 96–97
- Pathogens, POM, 11–12
- Patient-Reported Outcomes (PRO)
 consortium, 290
- Patient selection biomarkers, 185–187
 hypothesis independent
 approaches, 186–187

- PD. *See* Pharmacodynamic (PD)
 biomarkers, in oncology
- PD-PD models, POM study design,
 16
- Peptide hormone regulation, for
 obesity, 96–98
 CCK, 96
 GHSR, 97
 GLP1, 96
 GOAT, 97–98
 OXM, 96–97
- PERCIST. *See* PET Response Criteria in
 Solid Tumors
- Personalized medicine, 342
- PET. *See* Positron emission
 tomography
- PET Response Criteria in Solid Tumors
 (PERCIST), 238–239
- Pharmacodynamic (PD) biomarkers, in
 oncology, 180–183
 function, 180
 MTD, 181
 traditional Phase 1 dose selection,
 181–183
 POM, 182–183
- Pharmacological MRI (phMRI), 229
- Pharmacometrics. *See* Franchise
 disease-drug models;
 Modeling and simulation, in
 drug development
- Pharmacovigilance, 284–285
- Phase 1 trials. *See also* Proof of
 mechanism
 for biomarkers, for drug
 development, 207–209,
 219
 oncology drug development design,
 189
 type 2 diabetes medicine, 38
 biomarkers, 38
 DPP-4i, 38
 dynamic tests, 40, 42
 OGTTs, 39
 population selection, 39
 static measures, 40
- Phase 2 trials. *See also* Proof of
 concept
 for biomarkers, in drug
 development, 218–220, 221
 drug development, 330–331
 failure rates, 8
 glucose lowering medicine, 37–38
 HbA1c units, 37–38
 oncology drug development design,
 190
 success rate, 8
- Phase 3 trials, 22
- Phentermine, 101
- Phenylpropanolamine, 90
- phMRI. *See* Pharmacological MRI
- PK-PD models, POM study design,
 16
 for biomarkers, for drug
 development, 207–209
 fMRI biomarkers, in drug
 development, 230–233
- Plasma cholesterol levels, 63
- POC. *See* Proof of concept
- POM. *See* Proof of mechanism
- POMC. *See* Pro-opiomelanocortin
- Populations
 efficacy endpoint biomarkers,
 19–20
 in POC study designs, 17–19
 in POM study designs, 13–14
- Portfolio economics, 26–27
 commercial requirements, 27–28
- Positron emission tomography (PET)
 for atherosclerotic biomarkers,
 imaging biomarkers, in drug
 development, 224–228
 for antipsychotics, 224–226
 BP, 224–225
 case study, 227–228
 plasma kinetics, 226
 receptor occupancy, 224–225,
 247
 SERT, 226–227
 SSRIs, 226–227
- POV. *See* Proof of viability
- PPAR- α agonists, 76–77
- Pravastatin, 71
- Predictive Safety Testing Consortium
 (PSTC), 290–293. *See also*
 Critical Path Institute
- Primary care disease, 342
- PRO consortium. *See* Patient-Reported
 Outcomes consortium
- Probucol, 69
- Proof of concept (POC), 17–22
 $\alpha_v\beta_3$ integrin antagonists, 130
 biomarkers, 7
 lifecycle stage, 199
 calcilytic therapy, 142, 143–144
 decision criteria, commercial
 requirements, 27–28
 definition, 17
 experimental medicine
 organizations, 4
 indications screening strategy, 22

- Proof of concept (POC) (*cont.*)
- SARMs, in osteoporosis therapy, 136
 - study design considerations, 17–22
 - cost, 20–21
 - dose selection, 20
 - efficacy endpoints, 19–20
 - indications, 21–22
 - population, 17–20, 21–22
 - risk factors, 20–21
 - speed, 20–21
- Proof of mechanism (POM), 7–11, 16
- antibiotics, 12–13
 - MIC, 12–13
 - biomarkers, 7
 - behavioral v. biochemical, 10–11
 - decision criteria, 8–9
 - definition, 4
 - experimental medicine
 - organizations, 4
 - human indications screening, 23
 - pathogens, 11–12
 - pharmacodynamic biomarkers, 182–183
- Phase 1 studies, 13
- Phase 2, 7–8, 13
- preclinical studies, 8
- study design considerations, 13–16
- endpoints, 15
 - feasibility, 14–15
 - PD-PD models, 16
 - PK-PD models, 16
 - population, 13–14
 - risk factors, 14
 - validation of methods, 9–10
- Proof of viability (POV), 26–27
- Pro-opiomelanocortin (POMC), 92
- Proton magnetic resonance spectroscopy (H-MRS), 242–243
- PSTC. *See* Predictive Safety Testing Consortium
- Qualification, of biomarkers, 7
- Radiotracers. *See* Serotonin transporter radiotracers
- Receptor occupancy, 224–225, 247
- RECIST. *See* Response Evaluation Criteria in Solid Tumors
- Reconstituted and recombinant HDL/ApoA-I mimetic peptides, 77
- Remifentanyl, 232
- Response Evaluation Criteria in Solid Tumors (RECIST), 184–185
 - oncology imaging, 237
- Response to inflammation hypothesis, 64
- Response to injury hypothesis, 63–64
- Response to retention hypothesis, 64–65
- Reverse cholesterol transport, 67–68
- Rilapladib, 74
- Rimonabant, 42, 100
- Risperidone, 226
- Roden, Michael, 41
- Ronacaleret, 142–143
- Safety issues, type 2 diabetes medicine, 36, 46–49
 - FMD data, 47
- Safety scientists, 284
- SARMs. *See* Selective androgen receptor modulators
- Satiety-thermogenesis regulation, for obesity, 92–96
 - AMPK activation, 96
 - CB regulation, 95
 - GPCRs, 92
 - leptin levels, 92
 - MCH regulation, 94–95
 - neuropeptide expression, 92–94
 - nutrient sensation, 95–96
 - CPT1, 95
 - POMC activation, 92
 - serotonergic pathway regulation, 95
- SCD1. *See* Stearyl-CoA desaturase 1
- Schizophrenia, therapies under IMI, 282
- Sclerosteosis, 150
- Sclerostin inhibitors, 149–155
 - animal models, 151–154
 - monoclonal antibodies, 152–154
 - bone formation, 155
 - expression, 149–151
 - human data, 154–155
 - sclerosteosis, 150
 - Van Buchem disease, 150
- Secretory phospholipase A2 (sPLA2), 74
- Selective androgen receptor modulators (SARMs), 131–136
 - animal models, 132–134

- expression, 131–132
 human data, 134–136
 bone turnover, 135–136
 menopause and, 135
 POC mechanisms, 136
 Selective serotonin reuptake inhibitors (SSRIs), 226–227
 Semagacestat, 175–176
 Serotonin transporter (SERT)
 radiotracers, 168–169, 175
 PET imaging, 226–227
 Serotonergic pathway regulation, 95
 SERTs. *See* Serotonin transporter
 radiotracers
 Sibutramine, 42, 100
 Sims, Ethan, 90
 Simvastatin, 72
 SLx-4090, 74
 sPLA2. *See* Secretory phospholipase A2
 SSRIs. *See* Selective serotonin reuptake inhibitors
 Statins, 72
 Stearyl-CoA desaturase 1 (SCD1), 99
 Stepped hypoglycemic clamp, 48–49
 Stop-signal tasks, 174–175
 Surrogate endpoint biomarker, 5–6
 Systemic mechanisms, glucose
 lowering, 38–39
 insulin secretion, 38–39

 Tamoxifen, 186
 Target biomarker, 6, 196
 Task-evoked fMRI, 229
 Technical validation, 7, 197
 attribute selection, 205–207
 types, 206–207
 Teriparatide, 142–143
 Thyroid receptor- β agonists, 73
 Torcetrapib, 30–31, 76
 Phase 1 trials, 81
 Phase 2 study, 81
 Translational medicine, 1–32. *See also*
 Innovative Medicines
 Initiatives
 for atherosclerosis, 62–82
 biomarkers, 4, 5–7
 commercial profile, 27–32
 “blockbuster” drugs, 28
 decision making and, 29–31
 impact on survival, 27
 personalized medicine options,
 31–32
 requirements, 27–28
 commercial requirements, 27–28

 definition, 3
 drug discovery strategy, 3
 energy balance, 102–103
 experimental medicine
 organizations v., 4–5
 franchise disease–drug models for,
 307–308
 history, 4–5
 human indications screening,
 23–27
 costs, 26–27
 efficacy signals, 23–24
 Expl-IND approach, 24–26
 POM, 23
 portfolio economics, 26–27
 POV, 26–27
 neuroscience
 cognitive biomarkers, 174–175
 drug development for, 168–176
 imaging studies, 176
 semagacestat, 175–176
 SERT radiotracers, 168–169, 175
 short-term study efficacy,
 173–174
 obesity, 89–108
 atherosclerosis and, 62, 89
 biomarkers, 103–106
 drug targets, 93–94
 energy balance, 89
 hypertension from, 89
 peptide hormone regulation,
 96–98
 satiety-thermogenesis
 regulation, 92–96
 type 2 diabetes, 41–43, 89
 oncology, 180–191
 biomarkers, 180–187
 outcome, 183–185
 outcome biomarkers, 183–185
 patient selection biomarkers,
 185–187
 pharmacodynamic biomarkers,
 180–183
 Phase 1 study design, 189
 Phase 2 study design, 190
 preclinical work, 188–189
 osteoporosis, 115–158
 $\alpha_v\beta_3$ integrin antagonists,
 127–130
 antiresorptive therapy, 121–130
 biomarkers, 116–121
 BMD, 116, 118–119
 bone turnover, 116–118
 calcilytics, 136–144

- Translational medicine (*cont.*)
- cathepsin K inhibitors, 122–127
 - DKK-1 inhibitors, 144–149
 - drug development challenges, 116
 - osteoblasts, 130–155
 - presentation, 115
 - prevalence, 115
 - SARMs, 131–136
 - sclerostin inhibitors, 149–155
 - treatment therapies, 115
 - POC, 17–22. *See also* Proof of concept
 - biomarkers, 7
 - definition, 17
 - experimental medicine organizations, 4
 - study design considerations, 17–22
 - POM, 7–11, 16. *See also* Proof of mechanism
 - antibiotics, 12–13
 - biomarkers, 7
 - criteria, 8–9
 - experimental medicine organizations, 4
 - human indications screening, 23
 - pathogens, 11–12
 - Phase 2 trials, 7–8, 13
 - preclinical studies, 8
 - study design considerations, 13–16
 - validation, 9–10
 - type 2 diabetes, 35–56
 - adverse effects, 36
 - benefits, 36
 - β cell function, 35
 - cardiovascular benefits, 43
 - case studies, 49–56
 - complications, 35
 - drug classes, 35
 - drug failure, 35
 - efficacy, 37–46
 - glucose lowering, 37–41
 - HbA1c units, 56
 - hypoglycemia, 47–49
 - incidence rates, 35
 - obesity and, 41–43
 - phase I trials, 38
 - safety risks, 36, 46–49
 - Trastuzumab, 186
 - Triglycerides, lipoprotein metabolism, 67
 - Trilipix, 71
 - type 1 diabetes, C-peptide response preservation, 40
 - type 2 diabetes, translational medicine for, 35–56
 - adverse effects, 36
 - benefits, 36
 - β cells, 35
 - DMAD agents, 43–46
 - under IMI, 282
 - pathophysiology, 43
 - preservation, 43–46
 - biomarkers, 38
 - glycemic, 38
 - cardiovascular benefits, 43
 - dyslipidemia, 43
 - case studies, 49–56
 - 11-b-HSD1, 50–54
 - DPP-4i, 38, 49–50
 - HbA1c units, 54–56
 - complications, 35
 - drug classes, 35
 - drug failure, 35
 - efficacy, 37–46
 - β cells, 43–46
 - glucose lowering, 37–41
 - obesity, 41–43
 - franchise disease–drug models for, 308–309
 - glucose lowering, 37–41
 - biomarkers, 38
 - glucose-dependence, 38
 - glycemic biomarkers, 38
 - HbA1c units, 37–38
 - IVGTT, 41
 - MMTTs, 41
 - OGTTs, 39, 41
 - Phase 1 trials, 38
 - Phase 2 studies, 37–38
 - system perturbation
 - introduction, 40–41
 - systemic mechanisms, 38–39
 - HbA1c units, 56
 - case studies, 54–56
 - obesity and, 41, 43, 54–56
 - hypoglycemia, 47–49
 - ACCORD study, 47–48
 - drug development, 48
 - stepped clamps, 48–49
 - VADT, 47–48
 - under IMI, 282
 - incidence rates, 35
 - obesity and, 41–43, 89
 - HbA1c, 43

Cambridge University Press

978-0-521-88645-1 - Translational Medicine and Drug Discovery

Edited by Bruce H. Littman and Rajesh Krishna

Index

[More information](#)

- weight loss drugs, development
of, 41–43
- Phase 1 trials, 38
- biomarkers, 38
- DPP-4i, 38, 49–50
- safety risks, 36, 46–49
- cardiovascular, 46–47
- FMD data, 47
- hypoglycemia, 47–49
- UCP activation. *See* Uncoupling
protein activation
- UKPDS. *See* United Kingdom
Prospective Diabetes
Study
- Uncoupling protein (UCP) activation,
99
- United Kingdom Prospective Diabetes
Study (UKPDS), 44
- VADT. *See* Veterans Affairs Diabetes
Trial
- Validation
- biomarkers, 7, 195–203
- business value of, 200–202
- in drug development, 7,
195–203, 215–221
- lifecycle stages, 198–199
- MAC, 197, 199, 209–215
- principles, 196–197
- technical, 7
- terminology, 197–198
- translation, 197
- validity of, 197
- definition, 195
- MAC, 197, 199, 209–215
- clinical outcome linkage to,
211–212
- content of, 210
- fallback positions for, 211
- performance targets in,
210–211
- POM, 9–10
- technical, 197
- attribute selection, 205–207
- Validity, of biomarkers, 197
- Van Buchem disease, 150
- Varespladib, 74
- Vasella, Daniel, 28–29
- Veterans Affairs Diabetes Trial (VADT),
47–48
- Weight loss drugs, development of,
41–43
- Wnt signaling, 144–145
- Ziluton, 29–30
- Zonisamide, 101